Publications

1. Foster WK, Miller DS, Scougall CA, Kotlarski I, Colonno RJ, Jilbert AR. (2005) The effect of antiviral treatment with Entecavir on age- & dose-related outcomes of duck hepatitis B virus infection. J. Virol. 79(9): 5819-5832.
   
   
2. Mason WS, Jilbert AR, Summers J (2005). Clonal expansion of hepatocytes during chronic woodchuck hepatitis virus infection. Proc Natl Acad Sci (USA) 102: 1139–44
   
   
3. Miller DS, Foster WK, Burrell CJ, Jilbert AR (2005). Covalently Closed Circular DNA is the Predominant Form of Duck Hepatitis B Virus DNA that Persists Following Transient Infection. J. Virol. 79 (19) (in press).
   
   
4. Le Mire MF, Miller DS, Foster WK, Burrell CJ, Jilbert AR (2005). Covalently Closed Circular DNA is the Predominant Form of Duck Hepatitis B Virus DNA that Persists Following Transient Infection. J. Virol. 79(19): 12242-12252.
   
   
5. Mason WS, Litwin S, Summers J, Jilbert AR (2006). The importance of cell death in recovery from hepadnavirus infections. In “Framing the Knowledge of Viral Hepatitis”. Ed. R. Schinazi and E.R Schiff. IHL Press. pp 79-96.
   
   
6. Litwin S, Toll E, Jilbert AR, Mason WS (2006). The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: Theoretical considerations. Journal of Clinical Virology 34 Suppl. 1 (2005) S96–S107.
   
   
7. Miller DS, Halpern M, Kotlarski I, Jilbert AR (2006a). Vaccination of ducks with a whole-cell vaccine expressing duck hepatitis B virus core antigen elicits antiviral immune responses that enable rapid resolution of de novo infection. Virology. 348(2):297-308.
   
   
8. Miller DS, Kotlarski I, Jilbert AR (2006b). DNA vaccines expressing the duck hepatitis B virus surface proteins lead to reduced numbers of infected cells and protect ducks against the development of chronic infection in a virus dose dependent manner. Virology. 351 (1):159-169.